Total Payments
$1.5M
2024 Payments
$211,765
Companies
38
Transactions
1,291
Medicare Patients
1,059
Medicare Billing
$787,358
Payment Breakdown by Category
Consulting$696,538 (45.7%)
Other$630,445 (41.4%)
Travel$106,821 (7.0%)
Food & Beverage$42,687 (2.8%)
Research$28,655 (1.9%)
Education$17,990 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $696,538 | 231 | 45.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $360,110 | 158 | 23.6% |
| Honoraria | $270,335 | 91 | 17.7% |
| Travel and Lodging | $106,821 | 385 | 7.0% |
| Food and Beverage | $42,687 | 402 | 2.8% |
| Unspecified | $28,655 | 18 | 1.9% |
| Education | $17,990 | 6 | 1.2% |
Payments by Type
General
$1.5M
1,273 transactions
Research
$28,655
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $390,364 | 159 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $243,598 | 287 | $0 (2024) |
| MDD US Operations, LLC | $187,049 | 229 | $0 (2024) |
| Kyowa Kirin, Inc. | $141,818 | 99 | $0 (2024) |
| Acorda Therapeutics, Inc | $107,974 | 72 | $0 (2022) |
| ACADIA Pharmaceuticals Inc | $70,502 | 45 | $0 (2020) |
| ABBVIE INC. | $70,051 | 57 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $63,085 | 61 | $0 (2022) |
| Adamas Pharmaceuticals, Inc. | $51,744 | 49 | $0 (2021) |
| US WorldMeds, LLC | $32,440 | 71 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $211,765 | 141 | Amneal Pharmaceuticals LLC ($76,706) |
| 2023 | $238,606 | 233 | MDD US Operations, LLC ($102,094) |
| 2022 | $169,725 | 170 | Neurocrine Biosciences, Inc. ($59,586) |
| 2021 | $161,780 | 78 | Amneal Pharmaceuticals LLC ($69,658) |
| 2020 | $213,072 | 133 | Kyowa Kirin, Inc. ($47,583) |
| 2019 | $324,868 | 271 | Amneal Pharmaceuticals LLC ($99,474) |
| 2018 | $122,624 | 155 | Neurocrine Biosciences, Inc. ($27,975) |
| 2017 | $80,695 | 110 | ACADIA Pharmaceuticals Inc ($26,154) |
All Payment Transactions
1,291 individual payment records from CMS Open Payments — Page 1 of 52
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Honoraria | Cash or cash equivalent | $2,534.00 | General |
| Category: NEUROLOGY | ||||||
| 12/20/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/20/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/20/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2024 | ABBVIE INC. | VYALEV (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/18/2024 | ABBVIE INC. | VYALEV (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Honoraria | Cash or cash equivalent | $2,534.00 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | MDD US Operations, LLC | — | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| 12/06/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/06/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/06/2024 | ABBVIE INC. | VYALEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $36.62 | General |
| Category: NEUROLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | VYALEV (Drug) | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/03/2024 | ABBVIE INC. | VYALEV (Drug) | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 12/02/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,181.00 | General |
| 11/21/2024 | MDD US Operations, LLC | Gocovri (Drug) | Consulting Fee | Cash or cash equivalent | $920.00 | General |
| Category: AMANTADINE | ||||||
| 11/19/2024 | ABBVIE INC. | VYALEV (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2024 | MDD US Operations, LLC | — | Consulting Fee | Cash or cash equivalent | $5,951.25 | General |
| 11/15/2024 | MDD US Operations, LLC | — | Travel and Lodging | In-kind items and services | $255.95 | General |
| 11/15/2024 | MDD US Operations, LLC | — | Travel and Lodging | In-kind items and services | $247.43 | General |
| 11/15/2024 | MDD US Operations, LLC | — | Travel and Lodging | In-kind items and services | $230.01 | General |
| 11/15/2024 | MDD US Operations, LLC | — | Food and Beverage | In-kind items and services | $202.20 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-015 | ACADIA Pharmaceuticals Inc | $26,154 | 1 |
| Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | Biogen, Inc. | $1,642 | 13 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 PRX002 IN PARTICIPANTS WITH EARLY PARKINSON S DISEASE WITH A 52-WEEK BLINDED EXTENSION PASADENA | F. Hoffmann-La Roche AG | $374.16 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 PRX002 IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE WITH A 52-WEEK BLINDED EXTENSION PASADENA | F. Hoffmann-La Roche AG | $336.64 | 2 |
| A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 R-2-amino-3-phenylpropylcarbamate Hydrochloride in Subjects With Parkinson's Disease and Excessive Sleepiness | Jazz Pharmaceuticals Inc. | $148.87 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 240 | 28,401 | $730,639 | $185,016 |
| 2022 | 8 | 261 | 32,968 | $846,731 | $220,509 |
| 2021 | 7 | 259 | 26,565 | $521,092 | $173,562 |
| 2020 | 8 | 299 | 30,675 | $454,617 | $208,271 |
Total Patients
1,059
Total Services
118,609
Medicare Billing
$787,358
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 45 | 27,914 | $530,100 | $135,481 | 25.6% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 44 | 132 | $82,186 | $20,804 | 25.3% |
| 64646 | Injection of chemical for paralysis of nerve muscles on trunk, 1-5 muscles | Office | 2023 | 40 | 116 | $36,482 | $8,641 | 23.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 44 | 62 | $33,790 | $8,041 | 23.8% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 44 | 132 | $31,152 | $7,891 | 25.3% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2023 | 11 | 30 | $15,429 | $3,797 | 24.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 12 | 15 | $1,500 | $361.50 | 24.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 51 | 29,696 | $551,329 | $143,356 | 26.0% |
| J0587 | Injection, rimabotulinumtoxinb, 100 units | Office | 2022 | 12 | 2,800 | $99,805 | $26,738 | 26.8% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2022 | 45 | 126 | $78,661 | $20,678 | 26.3% |
| 64646 | Injection of chemical for paralysis of nerve muscles on trunk, 1-5 muscles | Office | 2022 | 42 | 112 | $29,408 | $8,140 | 27.7% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2022 | 45 | 125 | $29,914 | $7,918 | 26.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 42 | 56 | $30,520 | $6,614 | 21.7% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2022 | 13 | 41 | $22,456 | $6,038 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 12 | $4,638 | $1,027 | 22.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 50 | 26,106 | $337,698 | $124,561 | 36.9% |
| 64616 | Injection of chemical for destruction of nerve muscles on one side of neck excluding voice box accessed through the skin | Office | 2021 | 42 | 111 | $68,335 | $17,718 | 25.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 50 | 69 | $33,090 | $8,947 | 27.0% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Office | 2021 | 43 | 122 | $28,534 | $7,918 | 27.8% |
| 64646 | Injection of chemical for destruction of nerve muscles on trunk, 5 or more muscles | Office | 2021 | 39 | 97 | $23,362 | $7,067 | 30.3% |
| 64612 | Injection of chemical for destruction of nerve muscles on one side of face | Office | 2021 | 16 | 41 | $23,240 | $5,876 | 25.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 19 | 19 | $6,833 | $1,475 | 21.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 51 | 27,029 | $216,200 | $128,476 | 59.4% |
| J0587 | Injection, rimabotulinumtoxinb, 100 units | Office | 2020 | 13 | 3,150 | $47,250 | $29,673 | 62.8% |
| 64616 | Injection of chemical for destruction of nerve muscles on one side of neck excluding voice box accessed through the skin | Office | 2020 | 44 | 116 | $71,529 | $18,483 | 25.8% |
About Dr. Robert Hauser, MD
Dr. Robert Hauser, MD is a Neurology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558384743.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Hauser, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $211,765 received in 2024. These payments were reported across 1,291 transactions from 38 companies. The most common payment nature is "Consulting Fee" ($696,538).
As a Medicare-enrolled provider, Hauser has provided services to 1,059 Medicare beneficiaries, totaling 118,609 services with total Medicare billing of $787,358. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Tampa, FL
- Active Since 07/26/2006
- Last Updated 03/22/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1558384743
Products in Payments
- RYTARY (Drug) $246,591
- GOCOVRI (Drug) $158,869
- INGREZZA (Drug) $157,379
- NOURIANZ (Drug) $99,587
- INBRIJA (Drug) $78,802
- NUPLAZID (Drug) $70,502
- CREXONT (Drug) $66,350
- VYALEV (Drug) $50,721
- Nourianz (Drug) $39,231
- Gocovri (Drug) $31,620
- APOKYN (Drug) $19,646
- KYNMOBI (Drug) $16,156
- Ongentys (Drug) $15,088
- ONGENTYS (Drug) $12,690
- MYOBLOC (Biological) $10,759
- AUSTEDO (Drug) $9,410
- LATUDA (Drug) $8,621
- Xeomin (Biological) $8,504
- Radicava (Drug) $7,232
- APTIOM (Drug) $6,687
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Tampa
Derrick Robertson, M.d, M.D
Neurology — Payments: $2.3M
Neurology $2.3M
Selim Benbadis, Md, MD
Neurology — Payments: $2.3M
Neurology $2.3M
Dr. Mark Cascione, M.d, M.D
Neurology — Payments: $1.9M
Neurology $1.9M
David Rose, M.d, M.D
Neurology — Payments: $1.5M
Neurology $1.5M
Dr. Katherine Standley, Do, DO
Neurology — Payments: $1.3M
Neurology $1.3M
Dr. Tuan Vu, Md, MD
Neurology — Payments: $1.2M
Neurology $1.2M